Hepatic steatosis is the most distinctive feature of alcoholic liver disease (ALD). Our previous in vivo study showed that ligustrazine, a major active alkaloid isolated from Ligusticum chuanxiong Hort, attenuated alcohol-induced hepatic steatosis and in vitro study revealed that nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activation might be a prerequisite. This study was aimed to explore the in vivo function of Nrf2 in the protective effect of ligustrazine and illustrate downstream mechanisms. Nrf2 shRNA lentivirus was introduced to establish Nrf2-knockdown mice. Results showed that Nrf2 knockdown aggravated alcoholic liver injury and abolished the protective effect of ligustrazine, evidenced by elevated serum biomarkers and severe liver inflammation. Ligustrazine impressively ameliorated hepatic steatosis through inhibiting hepatic sterol regulatory element-binding protein-1c and inducing peroxisome proliferator-activated receptoralpha, which was abrogated by Nrf2 knockdown. Noteworthily, Nrf2 knockdown apparently reinforced the inductive effect of alcohol on hypoxia-inducible factor 1-alpha (HIF-1a). Ligustrazine weakened the stimulation of alcohol on HIF-1a expression, which was abrogated by Nrf2 shRNA lentivirus. Consistent results were obtained from in vitro study, implying that Nrf2/HIF-1a pathway participated in the modulation of ligustrazine. Gain-or loss-of-function analyses further revealed that Nrf2 siRNA and dimethyloxalylglycine, a HIF-1a agonist, abolished the inhibitory effect of ligustrazine, whereas HIF-1a siRNA mimicked the role of ligustrazine and even rescued the inhibitory effect of ligustrazine on ethanol-induced lipid accumulation in Nrf2-knockdown hepatocytes. Taken together, we concluded that ligustrazine attenuated alcohol-induced hepatic steatosis via a Nrf2/HIF-1a pathway-dependent mechanism.
which postpones the drug development for ALD. Targeted therapy drugs are urgently anticipated to be developed for solving this tough medical problem (Barve et al., 2008) .
Ligustrazine, an effective bioactive component of Ligusticum chuanxiong Hort, has been widely used in Chinese medicine and exhibited excellent pharmacological activities (Figure 1) . However, few studies focused on the effect of ligustrazine on ALD. Recently, we for the first time found that ligustrazine exerted potent protective effects on chronic alcohol-caused hepatic steatosis. Of interest was that ligustrzine activated nuclear factor (NF) (erythroid-derived 2) like 2 (Nrf2) in rat livers (Lu et al., 2015b) . Nrf2, except for its classic function as an antioxidant regulatory protein, was recently highlighted for its role in regulating hepatic lipid homeostasis. It was found that Nrf2-deficient mice suffered from serious hepatic steatosis in response to chronic alcohol administration (Wu et al., 2012) . Our in vitro study further revealed that Nrf2 activation was required for ligustrazine to reduce lipid accumulation in ethanol-treated hepatocytes (Lu et al., 2015a) . All these findings suggested that Nrf2 activation might be a precondition for ligustrazine to attenuate hepatic steatosis. Several natural molecules, serving as Nrf2 activators, have been proved to be liver-protective drugs (Kumar et al., 2014) . This work was to determine whether Nrf2 was a target for ligustrzine to alleviate hepatic steatosis in in vivo system.
Alcohol metabolism mainly occurred in liver. Alcohol is defined as a consumer of hepatic oxygen and always leads to intrahepatic hypoxia (Li et al., 2004) . Intrahepatic oxygen dynamics influence hepatic metabolism (Jungermann and Kietzmann, 2000) . Persistent severe hypoxia would cause mitochondrial dysfunctions, leading to impaired fatty acid oxidation and enhanced lipid synthesis (Lieber, 2004) . Hypoxia-inducible factor 1-alpha (HIF-1a) is a master modulator of transcriptional responses to hypoxia. Later study revealed that hepatic HIF-1a expression was apparently increased in alcohol-fed mice (Li et al., 2006) . Hepatocyte-specific HIF-1a activation obviously induced hepatomegaly and hepatic lipid accumulation in alcoholfed mice, while hepatic-specific deletion of HIF-1a prevented alcoholic effects in mice (Nath et al., 2011) . These findings consistently confirmed the importance of HIF-1a in modulating hepatic lipid metabolism. Interestingly, HIF-1a activation could be potentially inhibited by Nrf2, suggesting that there was a probable correlation between HIF-1a and Nrf2 Ma et al., 2003) . These discoveries directed us to investigate deeply into molecular mechanisms of ligustrazine suppression on alcoholic hepatic steatosis.
MATERIALS AND METHODS
Reagents and antibodies. Ligustrazine and dimethyloxalylglycine (DMOG) were purchased from Sigma (St Louis, Missouri, USA) and dissolved in dimethylsulfoxide (DMSO; Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) and sterile deionized water, respectively. Lentivirus vectors encoding negative control short hairpin RNA (NC shRNA) and Nrf2 shRNA (forward: gatccAAGCCTTACTCTCCCAGTGAATCGAAATTCACTGGGAGAG TAAGGCTTtttt, reverse: aattAAAAAAAAGCCTTACTCTCCC AGTGAATTTCGATTCACTGGGAGAGTAAGGCTTg) were constructed by Nanjing di rui biological technology Co., Ltd. (Nanjing, Jiangsu, China). Control siRNA, Nrf2 siRNA, and HIF-1a siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, California, USA). The primary antibodies against CD45 (20103-1-AP), F4/80 (18705-1-AP), and HIF-1a (20960-1-AP) were from Proteintech Group, Inc. (Rosemont, IL, USA). The primary antibodies against glutathione cysteine ligase modifier subunit (GCLM, sc-55586), NAD(P)H:quinone oxidoreductase 1 (NQO1, sc-376023), tumor necrosis factor-alpha (TNF-a, sc-1351), NF-jB (sc-372), sterol regulatory element-binding protein-1c , peroxisome proliferator-activated receptor-alpha (PPAR-a, sc-9000), and b-actin (sc-47778) were from Santa Cruz Biotechnology (Santa Cruz, California, USA). The primary antibody against NLR family, pyrin domain containing 3 (NLRP3, NBP1-77080) was from Novus Biologicals (Littleton, Colorado, USA). The primary antibodies against alpha-smooth muscle actin (a-SMA, ab32575) and fibronectin (ab183352) were purchased from Epitomics (San Francisco, California, USA). The primary antibody against a1(I) procollagen (234167) was purchased from Calbiochem (San Diego, California, USA). The primary antibodies against Nrf2 (12721) and I-kappaB alpha (I-jBa, 9242) and the horseradish peroxidase-conjugated secondary antibodies were obtained from Cell Signaling Technology (Danvers, Massachusetts, USA). The primers used in real-time PCR were from GenScript Co. Ltd. (Nanjing, Jiangsu, China).
Animals and experimental procedures. All experimental procedures were approved by the institutional and local committee on the care and use of animals of Nanjing University of Chinese Medicine (Nanjing, Jiangsu, China). All animals received human care in strict accordance to National Institutes of Health guidelines. Male ICR mice (20-25 g) were purchased from Nantong University (Nantong, Jiangsu, China). All mice were grown in the specific pathogen free clean room with a controlled condition of 21-25 C and a 12-h dark/light cycle during the whole experiment. Sixty mice were randomly divided into 5 groups (12 mice/group) according to different variables ( Figure 2 ). Mice in groups 1-5 were respectively administrated with NC shRNA lentivirus plus saline, NC shRNA lentivirus plus alcohol, Nrf2 shRNA lentivirus plus alcohol, NC shRNA lentivirus, alcohol plus ligustrazine, and Nrf2 shRNA lentivirus, alcohol plus ligustrazine. During the 4-week experiment, the lentivirus titer of 1 Â 10 8 TU/mice was injected to caudal vein of mice biweekly (Liu et al., 2016; Zhai et al., 2013; Zhang et al., 2013) . Alcohol (56%, v/v, 10 ml/kg) and ligustrazine (100 mg/kg) was given by gavage once every day. And ligustrazine was suspended equably in alcohol. At the end of experiment, all mice were weighed and blood was collected from orbital vein. Livers were harvested and weighed. Half of each liver was fixed in 10% neutral buffered formalin solution and embedded in paraffin for immunohistochemistry and immunofluorescence staining. The remaining livers were stored in liquid nitrogen for Oil Red O staining and extraction of RNA and total proteins.
Cell culture. Human LO2 hepatocytes were obtained from Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco's modified eagle medium (Invitrogen, Grand Island, New York, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Invitrogen, Merelbeke, Belgium), 100 U/ml of penicillin, and 100 lg/ml of streptomycin, and grown in a humidified atmosphere of 5% CO 2 and 95% air at 37 C. Alcohol (56%, 10 ml/kg) or combined with ligustrazine (100 mg/kg) was administrated orally once a day.
medium was introduced to prepare the 1000 ll transfection mixture. Finally, each well of 6-well plates was filled with 1000 ll transfection mixture for 24 h in the incubator. Control siRNA was used as a negative control.
Nile Red staining. Hepatocytes were treated with indicated reagents for 24 h. Then, cells were washed twice with phosphate buffer saline and fixed with 3% paraformaldehyde for 20 min. Nile Red (3.3 lg/ml) was introduced to stain intracellular lipid droplets. DAPI was used to stain cell nuclei. Images were obtained using a fluorescence microscope (Nikon, Tokyo, Japan). Results were from triplicate experiments.
Western blot analysis. Protein extraction and western blot analysis were performed as we previously described (Lu et al., 2015b) . The abundance of target proteins was accurately identified using Quantity Ones 4.4.1 (Bio-Rad Laboratories, Berkeley, California, USA) and expressed as fold changes after normalization to b-actin. Results were from triplicate experiments.
Real-time PCR analysis. Total RNA in liver tissues and LO2 cells was extracted using Trizol reagent (Sigma-Aldrich, St Louis, Missouri, USA) according to the protocol from manufacturer. Real-time PCR was performed as our prior description (Chen et al., 2002) . Primers were listed in Tables 1 and 2 . Results were from triplicate experiments.
Histology and immunohistochemistry. Liver slices were stained with hematoxylin and eosin (H&E) as we previously described in Fu et al. (2008) . Immunohistochemistry was performed using corresponding antibodies according to the previous description (Huang et al., 2014) . Immunofluorescence staining was performed as we previously described in Zhang et al. (2014) .
Biochemical analysis. Serum was isolated from whole blood after centrifugation and stored at À80 C for subsequent analyses.
Enzyme activities of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH), levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) in serum, and levels of TG and TC in murine liver tissues and human hepatocytes were detected using commercial assay kits according to the protocols from manufacturer (Nanjing Jiancheng Bioengeering Institute, Nanjing, Jiangsu, China). The absorbance values were measured using a SPECTRAmax microplate spectrophotometer (Molecular Devices, Sunnyvale, California, USA).
Statistical analysis. All data were presented as mean 6 SD, and the results were analyzed using GraphPad Prism Software Version 6.0 (GraphPad Software, La Jolla, California, USA). The significance of difference was determined by 1-way analysis of variance with the post hoc Dunnett's test. Values of P < .05 were considered statistically significant.
RESULTS

Nrf2-Knockdown Mice Were Successfully Established by Nrf2 shRNA Lentivirus
Previously we have found that ligustrazine attenuated alcoholic rat liver injury. To further verify the mechanism underlying, RNA interference technology was applied. To achieve a high efficacy of genetic knockdown, Nrf2 shRNA lentivirus was injected into caudal vein to generate Nrf2-knockdown mice. Hepatic Nrf2 expression was measured by real-time PCR and western blot analysis. Results showed that alcohol significantly reduced Nrf2 expression in liver tissues. Nrf2 shRNA lentivirus further blocked the expression of Nrf2 and abolished the stimulation of ligustrazine on Nrf2 expression in alcohol-fed mice. It was noticeable that ligustrazine had potent inductive effect on hepatic Nrf2 expression at both mRNA and protein levels under exposure to alcohol (Figs. 3A and B) . Consistent results were obtained from immunohistochemical staining for Nrf2 in murine liver tissues ( Figure 3C ). In addition, we found that ligustrazine significantly cancelled the inductive effect of alcohol on the expression of kelch-like ECH-associated protein 1 (Keap1), suggesting that ligustrazine could also inhibit ubiquitinationproteasomal degradation of Nrf2 (Supplementary Figure S1) . Under physiological condition, ligustrazine also increased the protein abundance of hepatic Nrf2 in mice. There was no statistic difference between the doses of 100 and 200 mg/kg (Supplementary Figure S2) . Results from immunohistochemical staining also demonstrated that the expression of NQO1 and GCLM, 2 well-recognized target genes of Nrf2, in murine livers was apparently inhibited by Nrf2 shRNA (Figs. 3D and E). Altogether, these data showed that shRNA-mediated gene knockdown was achieved and Nrf2-knockdown mice were generated for subsequent analyses.
Nrf2 Knockdown Abrogates the Protective Effect of Ligustrazine on Alcohol-Induced Liver Injury
Whether Nrf2 knockdown affected the protective effect of ligustrazine on alcohol-caused liver injury was investigated. Serum biomarkers for liver injury were then detected. Results showed that alcohol-induced increases in activities of serum AST, ALT, ALP, and LDH were further enhanced by Nrf2 shRNA lentivirus. 
Ligustrazine decreased these enzyme activities, which was reversed by Nrf2 shRNA lentivirus (Figs. 4A-D). H&E staining was performed to visually evaluate liver damage. Results exhibited that Nrf2 shRNA lentivirus reinforced the deleterious effect of alcohol on hepatic structure, evidenced by hepatic cord disorder and severe vacuolation. The hepatoprotective effect of ligustrazine was obviously eliminated by Nrf2 shRNA lentivirus ( Figure 4E ). In addition, inflammatory cell infiltration was measured by immunohistochemistry staining for CD45 and F4/80 in liver tissues. Results showed that CD45-and F4/80-positive cells were extensively increased and dominantly around central veins. Nrf2 shRNA lentivirus aggravated the alcohol effect but abolished the inhibitory effect of ligustrazine (Figs. 4F and G).
Immunofluorescence staining visually exhibited that the negative regulatory effect of ligustrazine on alcohol-induced TNF-a expression was apparently cancelled by Nrf2 shRNA lentivirus (Fig. 4H) . Western blot analysis indicated that alcohol increased the expression of hepatic TNF-a, NF-jB, and NLRP3 but reduced the expression of I-jBa. These changes were more significant in Nrf2-knockdown mice. Ligustrazine treatment protected mice against the effect of alcohol, while Nrf2 shRNA lentivirus cancelled the protective effect of ligustrazine ( Figure 4I ). Subsequent investigations suggested that chronic alcohol feeding stimulated the expression of a-SMA, fibronectin, and a1(I)procollagen, while ligustrazine inhibited the expression of these fibrotic genes. However, the inhibitory effect of ligustrazine was not observed in Nrf2-knockdown mice ( Figure 4J ).
Taken together, these results indicated that the potent protective effect of ligustrazine on alcohol-induced liver injury was attributed to activation of Nrf2.
Nrf2 Knockdown Abolishes the Suppressive Effect of Ligustrazine on Alcohol-Induced Hepatic Steatosis ALD is associated with many complications, with dyslipidemia the most common one occurred in the progression of disease. Dyslipidemia is universally characterized by excessive lipid accumulation in serum. Our results showed that ligustrazine apparently attenuated alcohol-induced increases in levels of serum TG, TC, and LDL-C. Nrf2 shRNA lentivirus served as a pusher for alcohol but an obstructer for ligustrazine. Of interest was that the level of serum HDL-C was not affected ( Figure 5A ). Hepatic steatosis is the most representative and prominent pathological feature of ALD. Herein, hepatic lipid contents were evaluated. Results showed that during the experimental period, murine ponderal growth was retarded under alcohol stimulation, which was further aggravated when Nrf2 knockdown. Ligustrazine treatment regained the ponderal growth of mice, which however was eliminated by Nrf2 shRNA lentivirus ( Figure 5B ). Liver index (ratio of liver and body weight) exhibited a reverse trend ( Figure 5C ). Oil Red O staining of liver tissues visually indicated that chronic alcohol administration augmented the number of lipid droplets in liver tissues. More obvious increases in lipid droplets were observed in alcohol-treated Nrf2-knockdown mice. Although ligustrazine decreased lipid contents, Nrf2 shRNA lentivirus neutralized ligustrazine action ( Figure 5D ). In consistence with the results from serological detection, ligustrazine significantly reduced alcohol-caused high levels of hepatic TG and TC, which was abrogated by Nrf2 shRNA lentivirus ( Figure 5E ). In addition, real-time PCR and western blot analyses showed that alcohol administration impressively enhanced SREBP-1c expression but weakened PPAR-a expression at both mRNA and protein levels. Ligustrazine clearly rectified the alcohol-induced lipometabolism disorder, characterized by decreased SREBP-1c and increased PPAR-a. However, in Nrf2-knockdown mice, the alcoholic effect was aggravated and the therapeutic effect of ligustrazine was abrogated (Figs. 5F and G). Immunofluorescence staining for SREBP-1c and PPAR-a in liver tissues visually confirmed the results of western blot analyses (Figs. 5H and I) . Collectively, our data consistently suggested that activation of Nrf2 was required for ligustrazine to protect murine livers against alcohol-induced steatosis.
Nrf2 Knockdown Impairs the Suppression of Ligustrazine on HIF-1a Expression
HIF-1a was known as a determinant factor in hepatic steatosis, which led us to further investigate the role of HIF-1a in the therapeutic effect of ligustrazine and its correlation with Nrf2. Results indicated that chronic alcohol administration induced the mRNA and protein expression of HIF-1a. The stimulative action of alcohol on HIF-1a expression was mildly reinforced by Nrf2 shRNA lentivirus but sharply impaired by ligustrazine. Nrf2 shRNA lentivirus even eliminated the ligustrazine effect (Figs. 6A and B). Immunofluorescence staining for HIF-1a verified the results of western blot analyses ( Figure 6C ). Then, an in vitro system was introduced and HIF-1a expression in ethanolstimulated human LO2 hepatocytes was detected. The verified experiments showed successful transfection of Nrf2 siRNA into hepatocytes (Supplementary Figure S3) . Ethanol significantly increased the expression of intracellular HIF-1a at mRNA and protein levels, and this stimulation was enhanced by Nrf2 siRNA. Ligustrazine dramatically suppressed the expression of HIF-1a in hepatocytes, which was abolished by Nrf2 siRNA (Figs. 6D and E). Immunofluorescence staining for HIF-1a visually verified the results above ( Figure 6F ). In summary, our findings suggested that ligustrazine could inhibit HIF-1a expression dependent on activating Nrf2.
Nrf2/HIF-1a Signaling Pathway Is Involved in the Alleviation of Intracellular Lipid Accumulation by Ligustrazine
Prior investigations have established a role of Nrf2 and HIF-la in the regulation of ligustrazine. Next, we were intended to elucidate whether Nrf2/HIF-1a pathway was required for ligustrazine to ameliorate ethanol-induced lipid accumulation in hepatocytes.
Results showed that HIF-1a siRNA effectively blocked the protein expression of HIF-1a in LO2 cells (Supplementary Figure S4A) . Nile . I and J, Western blot analyses of proteins related to liver inflammation and fibrosis. For the statistics of each panel in this figure, data are expressed as mean 6 SD. # P < .05, ## P < .01, and ### P < .001 versus group 1, *P < .05 and **P < .01 versus group 2, $ P < .05 and $$ P < .01 versus group 4.
Red and Oil Red O staining indicated that both Nrf2 siRNA and HIF-1a agonist DMOG abolished the inhibitory effect of ligustrazine on ethanol-induced deposition of lipid droplets in hepatocytes. HIF-1a siRNA could mimic the effect of ligustrazine and further rescue the protective effect of ligustrazine on ethanolinduced lipid accumulation in Nrf2-knockdown hepatocytes ( Figure 7A and Supplementary Figure S4B) . The levels of intracellular TG and TC were also evaluated. It was worth noting that HIF-1a siRNA could also weaken the antagonistic effect of Nrf2 siRNA on ligustrazine ( Figure 7B ). Real-time PCR and western blot analyses indicated that ligustrazine suppressed SREBP-1c expression but stimulated PPAR-a expression at both mRNA and protein levels, which could be abrogated by Nrf2 siRNA or DMOG. However, HIF-1a siRNA diminished the suppressive effect of Nrf2 siRNA on the protection of ligustrazine (Figs. 7C and D) .
Immunofluorescence staining for SREBP-1c and PPAR-a confirmed the results of western blot analyses (Figs. 7E and F) . To investigate whether HIF-1a facilitated hepatocyte steatosis by interacting with SREBP-1c and PPAR-a, LO2 cells were transiently transfected with luciferase reporter plasmids pGMSREBP-Lu or pGMPPAR-Lu. Luciferase assays demonstrated that ethanol significantly induced the luciferase reporter activity of SREBP, which was further enhanced by DMOG. Both ligustrazine and HIF-1a siRNA suppressed the luciferase activity of SREBP. The inhibitory effect of ligustrazine was abolished by DMOG. In addition, changes in the luciferase activity of PPAR exhibited a reverse trend to that of SREBP, suggesting an inhibitory effect of HIF-1a on the luciferase reporter activity of PPAR promoter. These data suggested that HIF-1a regulated hepatic steatosis possibly by enhancing the activity of SREBP promoter and weakening the activity of PPAR promoter. HIF-1a could be a signaling molecule for ligustrazine to regulate lipid homeostasis in hepatocytes by affecting lipid synthesis and degradation ( Supplementary Figs. S5A and B). In conclusion, these data demonstrated that ligustrazine prevented hepatocytes from ethanol-led accumulation of lipid droplets in a Nrf2/HIF-1a-dependent mechanism. and PPAR-a in liver tissues. H and I, Immunofluorescence staining for SREBP-1c and PPAR-a in liver tissues (original magnification, 40Â). For the statistics of each panel in this figure, data are expressed as mean 6 SD. #P < .05, ## P < .01, and ### P < .001 versus group 1, *P < .05, **P < .01, and ***P < .001 versus group 2, $ P < .05, $$ P < .01, and $$$ P < .001 versus group 4.
DISCUSSION
Hepatic steatosis is the most remarkable pathological feature of ALD. Drugs targeting at ameliorating hepatic steatosis have the potential to be promising therapeutic strategies for ALD. However, few drugs have been approved by WHO for ALD treatment because of lack of a complete understanding of the mechanisms underlying drug action. Our previous study has confirmed the excellent efficacy of ligustrazine on alleviating chronic alcohol-induced hepatic steatosis in rats (Lu et al., 2015b) . And this work was aimed to further explore the explicit action mechanism for ligustrazine to improve hepatic steatosis. First, we found that ligustrazine exerted beneficial therapeutic effects on ALD mice, which was consistent with our previous study (Lu et al., 2015b) . Mechanistically, we for the first time found that activation of Nrf2 was required for ligustrazine to alleviate ethanol-induced hepatic steatosis, wherein Nrf2/HIF1a pathway played a mediating role. Previously, we have confirmed the critical role of ligustrazine in inhibiting ethanol-induced lipid accumulation in rats and hepatocytes. Notably, Nrf2 expression was significantly decreased in livers and hepatocytes exposed to ethanol but increased under ligustrazine treatment (Lu et al., 2015a,b) . This discovery directed us to investigate whether Nrf2 was a target for ligustrazine to work. In this study, Nrf2-knockdown mice were generated by injection with Nrf2 shRNA lentivirus.
First, we investigated whether Nrf2 was a prerequisite for ligustrazine to relieve chronic alcohol-induced liver injury, inflammation and fibrogenesis. To establish an ALD model, mice was orally administrated with alcohol (56%, v/v, 10 ml/kg) FIG. 6 . Nrf2 knockdown impairs the suppression of ligustrazine on HIF-1a expression. Mice were grouped: group 1, NC shRNA lentivirus plus saline; group 2, NC shRNA lentivirus plus alcohol; group 3, Nrf2 shRNA lentivirus plus alcohol; group 4, NC shRNA lentivirus, alcohol plus ligustrazine; group 5, Nrf2 shRNA lentivirus, alcohol plus ligustrazine. n ¼ 12. A, Real-time PCR analyses of HIF-1a in livers. B, Western blot analyses of HIF-1a in liver tissues. C, Immunofluorescence staining for HIF-1a in liver tissues (original magnification, 40Â). For the statistics of panels above, data are expressed as mean 6 SD. ## P < .01 and ### P < .001 versus group 1, **P < .01 versus group 2, and $$ P < .01 versus group 4. Human hepatocyte LO2 cells were treated with DMSO (0.02%, w/v) and/or ethanol and/or ligustrazine and/or Nrf2 siRNA at indicated doses for 24 h. D, Real-time PCR analyses of HIF-1a in hepatocytes. E, Western blot analyses of HIF-1a in hepatocytes. F, Immunofluorescence staining for HIF-1a in hepatocytes (original magnification, 40Â). For the statistics of these panels, data are expressed as mean 6 SD. ## P < .01 and ### P < .001 versus DMSO, * P < .05 versus DMSO plus ethanol, and $$ P < .01 versus ethanol plus ligustrazine.
for 4 weeks. Serum liver enzymes were first detected because they were recognized as sensitive indicators for liver injury. Intracellular enzymes, including AST, ALT, ALP, and LDH, will leak into the circular system when hepatocytes are damaged. We observed that chronic alcohol feeding obviously increased these enzyme activities in serum and caused noticeable histopathological changes of liver tissues, which were more obvious in Nrf2-knockdown mice. Although ligustrazine exhibited potent protective effects, Nrf2 shRNA lentivirus abrogated these protective effects. The development of chronic alcohol-induced liver injury is always accompanied by liver inflammation, which is characterized by leukocyte recruitment and macrophage infiltration (Akira et al., 2013; Kelly et al., 2007) . CD45 is a specific marker of leukocyte (Delima et al., 2012) . And F4/80 is a specific marker of Kupffer cell/macrophage (Tomita et al., 2014) . In this study, immunohistochemical staining for CD45 and F4/80 was performed to evaluate the infiltrated degrees of inflammatory cells. Results showed an increase in CD45-and F4/80-positive cells in alcohol-treated group but a decrease in those in ligustrazine-treated group. Nrf2 shRNA lentivirus, however, dramatically diminished the curative effect of ligustrazine. Subsequently, key proteins associated with inflammation were detected by western blot analyses. Consistent results further confirmed that ligustrazine ameliorated alcohol-induced hepatic inflammation by activating Nrf2. This discovery was consistent with previous studies which revealed that activation of Nrf2 could suppress inflammation in various diseases (Dong and Ma, 2015; Keleku-Lukwete et al., 2015; Sun et al., 2015) . Chronic alcohol administration-induced liver injury and inflammation usually progress into fibrosis without effective . For the statistics of the panels above, data are expressed as mean 6 SD. ## P < .01 and ### P < .001 versus DMSO, * P < .05 and ** P < .01 versus DMSO plus ethanol, $ P < .05, $$ P < .01, and $$$ P < .001 versus ethanol plus ligustrazine, & P < .05, && P < .01, and &&& P < .001 versus ethanol, ligustrazine plus Nrf2 siRNA.
therapies. Hepatic stellate cell (HSC) is an important mediator in the process of inflammation-fibrosis-carcinoma axis . Chronic liver inflammation stimulates HSC activation (Friedman, 2003) . In addition, ethanol or its metabolic intermediate acetaldehyde could directly stimulate collagen and fibrotic gene expression in HSC independent of hepatocyte injury (Page et al., 2015; Svegliati-Baroni et al., 2001 , 2005 . Therefore, expression of fibrotic genes in liver tissues was detected. It was found that ligustrazine notably reduced the expression of a-SMA, fibronectin, and a1(I) procollagen, suggesting that ligustrazine could attenuate ALD-related hepatic fibrosis. This finding was consistent with our prior studies (Lu et al., 2015b; Wu et al., 2015) . Nevertheless, the inhibitory effect of ligustrazine on alcohol-induced hepatic fibrosis was abolished by Nrf2 shRNA lentivirus. It was consistent with the prior study that Nrf2 activation could alleviate alcohol-and CCl 4 -induced hepatic fibrosis (Li et al., 2014) . Herein, we creatively confirmed that the effects of ligustrazine on alcohol-induced liver injury, inflammation, and fibrosis were based on Nrf2 activation. Hyperlipidemia is usually induced by alcohol intake, for the reason that chronic alcohol exposure could stimulate the release of free fatty acids from adipose tissue into blood (Sozio et al., 2010; Yuasa et al., 2000; Zhou et al., 2008) . Hyperlipidemia is characterized by abnormal states of TG, TC, LDL-C, and HDL-C in serum. On this basis, lipid contents in serum were detected using commercial kits. It was worth noting that Nrf2 shRNA lentivirus could significantly eliminate the effect of ligustrazine on improving alcohol-induced hyperlipidemia. Further, hepatic lipid accumulation was visually evaluated by Oil Red O staining and accurately quantified by measurement of hepatic TG and TC. Results clearly showed that Nrf2 shRNA lentivirus could not only enhance the alcoholic effect on inducing lipid deposition but also abrogate the improving effect of ligustrazine. The discoveries directly confirmed that ligustrazine attenuated alcohol-induced hepatic steatosis by activating Nrf2. Hepatic steatosis is attributed to lipid metabolism disorder. SREBP-1c induces fatty acid synthesis and PPAR-a promotes fatty acid oxidation, both of which serve as central regulators of hepatic lipid metabolism. Appropriate modulation of SREBP-1c and PPAR-a has been considered as a favorable strategy for balancing hepatic lipid metabolism in alcoholic rats (Zeng et al., 2012) . Consistent with our previous findings, ligustrazine decreased the expression of SREBP-1c but enhanced the expression of PPAR-a at transcriptional and translational levels (Lu et al., 2015b) . More importantly, Nrf2 shRNA lentivirus significantly reversed the effect of ligustrazine. This discovery consolidated the prior concepts that Nrf2 could directly regulate SREBP-1c in liver (Huang et al., 2010) and Nrf2 activation could enhance the efficiency of mitochondrial fatty acid oxidation (Ludtmann et al., 2014) . Immunofluorescence staining for SREBP-1c and PPAR-a was also performed in our study to intuitively confirm our results. Recently, it has emerged that HIF-1a played a critical role in modulating hepatic steatosis. However, few studies illuminated whether there was a role of HIF-1a in the protection of ligustrazine against alcohol-induced hepatic steatosis. In the present study, we clarified the effect of ligustrazine on HIF-1a expression and the correlation between Nrf2 and HIF-1a in the regulatory process. Our results showed that alcohol could increase the expression of HIF-1a, which was consistent with the previous study (Li et al., 2006) . Further, Nrf2-knockdown mice exhibited higher levels of hepatic HIF-1a when exposed to alcohol, suggesting that Nrf2 might serve as a repressor of HIF-1a. Ligustrazine inhibited alcohol-induced HIF-1a expression in liver tissues. Yet Nrf2 shRNA lentivirus significantly abrogated the inhibitory effect of ligustrazine on HIF-1a expression, suggesting that ligustrazine might regulate Nrf2/HIF-1a pathway in liver. In the next experiments, human LO2 hepatocytes were treated with ethanol (100 mM) for 24 h to establish an in vitro model of ALD according to our previous study (Lu et al., 2015a) . Consistent results with in vivo studies were obtained from in vitro ones.
Based on our prior findings that Nrf2/HIF-1a pathway was regulated by ligustrazine, next work was focused on investigating whether this pathway mediated the inhibition of intracellular lipid accumulation by ligustrazine. Intracellular lipid contents were visually determined by Nile Red staining and accurately determined by intracellular TG and TC levels. As expected, these data consistently confirmed the role of Nrf2 in ameliorating lipid accumulation in hepatocytes using Nrf2 siRNA. We also observed that DMOG, a specific agonist of HIF1a, had a similar effect to Nrf2 siRNA on abolishing the suppressive effect of ligustrazine on lipid deposition. However, HIF-1a siRNA rescued the effect of ligustrazine in Nrf2-knockdown hepatocytes, suggesting Nrf2/HIF-1a pathway was participated in inhibiting lipid accumulation by ligustrazine. Furthermore, Nrf2/HIF-1a pathway was involved in regulating SREBP-1c and PPAR-a expression by ligustrazine.
In conclusion, our work not only verified that Nrf2 was a prerequisite for ligustrazine to improve alcohol-induced hepatic steatosis but also uncovered that HIF-1a could be an important factor downstream of Nrf2 in the therapeutic process (Figure 8) . Our work provides novel insights into the mechanisms behind the ligustrazine effect.
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